A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
Pfizer
Obsidian Therapeutics, Inc.
M.D. Anderson Cancer Center
Filamon LTD
Mayo Clinic
Ankyra Therapeutics, Inc
Washington University School of Medicine
University of Florida
University of Nebraska
Elephas
Novartis
Elephas
Cancer Research UK
Massive Bio, Inc.
British Columbia Cancer Agency
Washington University School of Medicine
University of Florida
Delfi Diagnostics Inc.
Medicenna Therapeutics, Inc.
DEKA Biosciences
Columbia University
University of Arizona
Tempus AI
Turnstone Biologics, Corp.
Revolution Medicines, Inc.
Arbeitsgemeinschaft medikamentoese Tumortherapie
Stanford University
Cedars-Sinai Medical Center
Checkpoint Therapeutics, Inc.
Taproot Health
Iovance Biotherapeutics, Inc.
VitaMed Research LLC
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sanguine Biosciences
National Cancer Institute (NCI)
Klus Pharma Inc.
Revolution Medicines, Inc.
Bristol-Myers Squibb
Revolution Medicines, Inc.
BioNTech SE
SpeciCare
Lumos Pharma
Celgene
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center
CureOne
University of Texas Southwestern Medical Center
Santa Maria Biotherapeutics
OHSU Knight Cancer Institute